Podcast
25 Feb 2022

Podcast: The CDMO Response to COVID-19

The coronavirus pandemic has been incredibly disruptive for all facets of life around the globe, exerting extreme pressure on practically all industry sectors and severely impacting the usual day-to-day interactions they have become accustomed to. The pharmaceutical industry has been thrust into the vanguard of this global crisis, not only in its quest to find effective vaccines or therapeutics to fight the virus but also in its responsibility to continue to manufacture life-changing and essential medicines and ensure they are delivered to patients.

Even before the pandemic struck, pharma and biotech have been steadily increasing their outsourcing to contract development and manufacturing organisations (CDMOs) not only to cut costs and have access to manufacturing capacity but also to better deploy their resources and gain access to expertise in other phases of the product lifecycle.

This podcast was originally aired as part of the CPHI Festival of Pharma.

Content provided by our supplier

FAMAR ANONYMOUS INDUSTRIAL COMPANY OF PHARMACEUTICALS AND COSMETICS

  • GR
  • 2020
    On CPHI since
  • 3
    Certificates
  • 1000 - 4999
    Employees
Company types
Contract Service
Manufacturer/Innovator

Other Content from FAMAR ANONYMOUS INDUSTRIAL COMPANY OF PHARMACEUTICALS AND COSMETICS (2)